MARKET

KAPA

KAPA

KAIROS PHARMA LTD
AMEX
0.6354
+0.0831
+15.05%
Opening 11:34 02/27 EST
OPEN
0.5999
PREV CLOSE
0.5523
HIGH
0.6500
LOW
0.5815
VOLUME
654.14K
TURNOVER
--
52 WEEK HIGH
2.110
52 WEEK LOW
0.4000
MARKET CAP
13.23M
P/E (TTM)
-2.0867
1D
5D
1M
3M
1Y
5Y
1D
Kairos Pharma Signs Term Sheet To Acquire Two Oncology Assets From Celyn Therapeutics; Stock Up
NASDAQ · 20h ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 1d ago
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
TipRanks · 1d ago
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
TipRanks · 1d ago
Kairos Pharma Signs Deal To Acquire Two Experimental Lung Cancer Drug Candidates, Financial Terms Undisclosed
Benzinga · 1d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 1d ago
*Kairos Pharma: Transaction to Add CL-273, a pan-EGFR Inhibitor, and CL-741, a Phase 1-Ready c-MET Inhibitor >KAPA
Dow Jones · 1d ago
*Kairos Pharma Signs Term Sheet for Strategic Asset Acquisition of 2 Clinical Oncology Assets From Celyn Therapeutics
Dow Jones · 1d ago
More
About KAPA
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.

Webull offers Kairos Pharma Ltd stock information, including AMEX: KAPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KAPA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KAPA stock methods without spending real money on the virtual paper trading platform.